Batavia Biosciences and Valneva Collaborate to Accelerate Development of Low-cost Inactivated Polio Vaccine
Leiden, Netherlands and Saint-Herblain, France, June 15, 2020 Batavia Biosciences (Batavia) and Valneva Sweden AB, the Swedish subsidiary of Valneva SE (Valneva), today announced that they have entered into a collaboration agreement to accelerate market-access of a low-cost inactivated polio vaccine (IPV).
- Leiden, Netherlands and Saint-Herblain, France, June 15, 2020 Batavia Biosciences (Batavia) and Valneva Sweden AB, the Swedish subsidiary of Valneva SE (Valneva), today announced that they have entered into a collaboration agreement to accelerate market-access of a low-cost inactivated polio vaccine (IPV).
- The IPV vaccine is based on the Sabin vaccine strains (sIPV), which Batavia has successfully obtained from the World Health Organization (WHO).
- Under the terms of the agreement, Valneva will manufacture the sIPV vaccine for clinical trial purposes in its state-of-the-art GMP polio manufacturing facility operated under GAPIII2 polio containment in Solna, Sweden, using Batavias process.
- The company focuses on the early stages of product development including cell line generation, upstream process development, purification development, product characterization and clinical manufacturing.